



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Digitoxin

| | | | | | | | | | | | | | |
|---------------------------|--|---------|-------|---------|--|-----|---------|------------|-------|---------|--|-------|--------|
| Cat. No.: | HY-B1357 | | | | | | | | | | | | |
| CAS No.: | 71-63-6 | | | | | | | | | | | | |
| Molecular Formula: | C ₄₁ H ₆₄ O ₁₃ | | | | | | | | | | | | |
| Molecular Weight: | 764.94 | | | | | | | | | | | | |
| Target: | Bcl-2 Family; Caspase; Apoptosis; HSV; Na ⁺ /K ⁺ ATPase; Calcium Channel | | | | | | | | | | | | |
| Pathway: | Apoptosis; Anti-infection; Membrane Transporter/Ion Channel; Neuronal Signaling | | | | | | | | | | | | |
| Storage: | <table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>2 years</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 year</td> </tr> </table> | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 2 years | | -20°C | 1 year |
| Powder | -20°C | 3 years | | | | | | | | | | | |
| | 4°C | 2 years | | | | | | | | | | | |
| In solvent | -80°C | 2 years | | | | | | | | | | | |
| | -20°C | 1 year | | | | | | | | | | | |



SOLVENT & SOLUBILITY

| | | | | | |
|---|--|--------------------------|--------------|-----------|------------|
| In Vitro | DMSO : 100 mg/mL (130.73 mM; Need ultrasonic) | | | | |
| | | Solvent Concentration | Mass 1 mg | 5 mg | 10 mg |
| | Preparing Stock Solutions | 1 mM | 1.3073 mL | 6.5365 mL | 13.0729 mL |
| | | 5 mM | 0.2615 mL | 1.3073 mL | 2.6146 mL |
| 10 mM | | 0.1307 mL | 0.6536 mL | 1.3073 mL | |
| Please refer to the solubility information to select the appropriate solvent. | | | | | |
| In Vivo | <ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.27 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.27 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.27 mM); Clear solution | | | | |

BIOLOGICAL ACTIVITY

| | | | | |
|-------------------------------------|---|-----------|-----------|-----|
| Description | Digitoxin is an anti-cancer agent. Digitoxin induces apoptosis, inhibits influenza cytokine storm, causes DNA double-stranded breaks (DSBs) and blocks the cell cycle at the G2/M phase. Digitoxin induces calcium uptake into cells by forming transmembrane calcium channels and can be used for research of heart failure ^{[1][2][3][4][5]} . | | | |
| IC₅₀ & Target | Bcl-2 | Caspase-9 | Caspase 3 | Bax |
| | HSV-1 | | | |

In Vitro

Digitoxin (0-80 nM, 72 h) compromised cell survival in PC12 cells^[1].
 Digitoxin (4-1000 nM, 24-48 h) has an antitumor effects in MHCC97H, A549, HCT116 and HeLa cells^[3].
 Digitoxin (4-100 nM, 24-48 h) disrupts the cell cycle in HeLa cells^[3].
 Digitoxin (20-500 nM, 48 h) activates mitochondrial apoptosis in HeLa cells^[3].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
 Cell Viability Assay^[3]

| | |
|------------------|---|
| Cell Line: | MHCC97H, A549, HCT116 and HeLa cells |
| Concentration: | 4-1000 nM |
| Incubation Time: | 24 h, 48 h |
| Result: | Decreased the viability of these cancer cells in a dose- and time-dependent manner, with the IC ₅₀ values ranging from 0.075 to 0.395 μM following digitoxin treatment for 24 h and from 0.028 to 0.077 μM following digitoxin treatment for 48 h. |

Cell Cycle Analysis^[3]

| | |
|------------------|---|
| Cell Line: | HeLa cells |
| Concentration: | 4 nM, 20 nM, 100 nM |
| Incubation Time: | 24 h, 36 h, 48 h |
| Result: | Increased cell population in the G2/M phase from 16.27 to 18.36, 23.46 and 31.51% at concentrations of 20 nM for 12, 24 and 36 h. Increased average cell population in the G2/M phase from 16.27 to 28.07% at concentrations of 4, 20 and 100 nM for 24 h. Significantly decreased the protein expression levels of total CDK1 and phosphorylated CDK1. |

Apoptosis Analysis^[3]

| | |
|------------------|---|
| Cell Line: | HeLa cells |
| Concentration: | 20 nM, 100 nM, 500 nM |
| Incubation Time: | 48 h |
| Result: | Upregulated Bax expression and unaltered Bcl-2 expression. Significantly increased the expression of cytochrome c. |

In Vivo

Digitoxin (1-2 mg/kg, Intraperitoneal injection, once a day for 19 days) has anticancer effects in nude mice^[3].
 Digitoxin (0.3-3 μg/kg, Intraperitoneal injection, once a day for 4 days) blocks the host over-production of cytokines in the cotton rat lung^[4].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| | |
|-----------------|--|
| Animal Model: | nude mice harboring HeLa tumor xenografts ^[3] |
| Dosage: | 1 mg/kg, 2 mg/kg |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Decreased the tumor volume from 330.71±45.61 to 214.56.93±73.25 mm. Strongly increased the protein levels of cleaved caspase-3. |

Reduced the number of Ki-67-positive cells.

Animal Model: cotton rats^[4]

Dosage: 0.3 µg/kg, 1 µg/kg, 3 µg/kg

Administration: Intraperitoneal injection (i.p.)

Result: Blocked cytokine storm.
Differentially affected cytokine expression.
Left immune cell density intact in virus-infected lung.

CUSTOMER VALIDATION

- Gynecol Oncol. 2024 Jul 5;188:162-168.
- Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868.
- University of Saskatchewan. 2020 Jun 22.
- Nat Metab. 2019 Nov;1(11):1074-1088.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Haux J. Digitoxin is a potential anticancer agent for several types of cancer [J]. Medical hypotheses, 1999, 53(6): 543-548.
- [2]. Su C T, Hsu J T A, Hsieh H P, et al. Anti-HSV activity of digitoxin and its possible mechanisms [J]. Antiviral research, 2008, 79(1): 62-70.
- [3]. Gan H, Qi M, Chan C, et al. Digitoxin inhibits HeLa cell growth through the induction of G2/M cell cycle arrest and apoptosis in vitro and in vivo [J]. International Journal of Oncology, 2020, 57(2): 562-573.
- [4]. Pollard B S, Blanco J C, Pollard J R. Classical drug digitoxin inhibits influenza cytokine storm, with implications for COVID-19 therapy [J]. in vivo, 2020, 34(6): 3723-3730.
- [5]. Arispe N, et al. Heart failure drug digitoxin induces calcium uptake into cells by forming transmembrane calcium channels [J]. Proceedings of the National Academy of Sciences, 2008, 105(7): 2610-2615.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA